Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 14/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.57 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 4/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.54 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008061 | 0.89 | CDK1 (0.59) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL8677222 | 0.87 | CDK1 (0.57) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL3826045 | 0.86 | CDK1 (0.56) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL2098867 | 0.86 | CDK1 (0.63) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL7099130 | 0.84 | CDK1 (0.69) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL7006036 | 0.81 | ADORA2A (0.66) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL3877499 | 0.79 | CDK1 (0.53) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL2310972 | 0.79 | CDK1 (0.58) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL7008067 | 0.78 | CDK1 (0.57) | CDK1CCNB1CCNB2CCNB3CDK2 | |
| SCHEMBL3677942 | 0.74 | CDK1 (0.55) | CDK1CCNB1CCNB2CCNB3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2003-10-02 | — | — | US | claimed |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIGUE (C.N.R.S.) | 2002-04-25 | — | — | US | claimed |
| US-20030191086-A1 | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof | USTAV EXPERIMENTALNI BOTANIKY AV CR | 2003-10-09 | — | — | US | disclosed |
| EP-1147108-B1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | USTAV EX BOTAN AKADEMIE VED CE (CZ) | 2003-08-13 | — | — | EP | disclosed |
| US-6552192-B1 | Inhibiting cyclin dependent kinase proteins, viruses, and immunostimulation; antimitotic, antiviral, anticancinogenic, antidegenerative, immunosuppressive | USTAU EXPERIMENTALNI BOTANIKY AV-CR (CZ) | 2003-04-22 | — | — | US | disclosed |
| EP-1147108-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191086-A1 | Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof | CDK4, CDK5, CCNI | CDK1 6/4885CCNB1 63/4885CCNB2 56/4885 |
| US-20030186999-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885CCNB1 340/4885CCNB2 456/4885 |
| US-20020049218-A1 | Purine derivatives having, in particular, antiproliferative properties, and their biological uses | PNP, TYMP, NUDT1 | CDK1 501/4885CCNB1 340/4885CCNB2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.